Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 5/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026547 | 0.93 | AHCY (0.35) | MAPK14 | |
| SCHEMBL1027271 | 0.91 | MAPK14 (0.35) | DPP9DPP8MAPK14HTR2AHTR2C | |
| SCHEMBL1025223 | 0.89 | AHCY (0.35) | MAPK14 | |
| SCHEMBL1028634 | 0.88 | MAPK14 (0.35) | DPP9DPP8MAPK14HTR2AHTR2C | |
| SCHEMBL11974078 | 0.87 | AHCY (0.45) | DPP9DPP8MAPK14HTR2AHTR2C | |
| SCHEMBL11973988 | 0.84 | AHCY (0.45) | DPP9DPP8MAPK14HTR2AHTR2C | |
| SCHEMBL1027072 | 0.84 | AHCY (0.37) | MAPK14NAMPTCHRM1 | |
| SCHEMBL1026331 | 0.83 | DPP8 (0.31) | DPP9DPP8MAPK14DPP7 | |
| SCHEMBL1025705 | 0.82 | DPP9 (0.36) | DPP9DPP8NAMPTDPP7DPP4 | |
| SCHEMBL1028903 | 0.82 | RXRA (0.42) | DPP9DPP8HTR2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | DPP9 1542/4885DPP8 2320/4885MAPK14 1666/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | DPP9 1760/4885DPP8 2916/4885MAPK14 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.